Breaking News

Norwich Names Pharma Development VP

January 17, 2013

Arnold to lead product development and technical services

Kristin Arnold, Ph.D. has been appointed vice president of product development and technical services (PDTS) at Norwich Pharmaceuticals. Dr. Arnold will provide strategic leadership for the PDTS group that includes R&D, GMP pilot scale manufacturing, analytical development and validation, and testing services. She reports to chief executive officer, Doug Drysdale.
 
Prior to joining the company, Dr. Arnold held positions with URL Pharma as senior vice president of Product Development, Alpharma as senior director R&D, FMC Corp., Ecogen, and Monsanto.
 
"We are pleased to welcome Kristin Arnold to Norwich and look forward to her contributions to the PDTS group and the organization," said Mr. Drysdale. "Her expertise in product development from product conception through market launch will be an advantage for our customers and she will be a strong addition to our leadership team."

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016